Latest Factor VII Stories
LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.
The use of recombinant activated factor 7 (rFVIIa) â€“ a drug used to treat bleeding in hemophiliacs â€“ in patients without hemophilia is not recommended because of the potential for adverse events.
LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).
LAGUNA NIGUEL, Calif., Nov. 3, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the appointment of Karen A. Dawes to the Company's Board of Directors. Ms.
HOBOKEN, N.J., Nov.
WAYNE, N.J., Oct. 26 /PRNewswire/ -- Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives.
LAGUNA NIGUEL, Calif., Oct. 19 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.
PRINCETON, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Novo Nordisk announced today that the U.S.
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the U.S.
Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.